The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell ...

Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...

A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.